Health Care

Investor insights: Doximity’s recent insider purchase shows disciplined liquidity management and steady confidence, highlighting its competitive edge in physician networking and digital health growth.

Corcept Insider Selling: James N. Wilson’s 10‑b‑5‑1 plan sale shows disciplined liquidity moves, not a confidence hit—investors can still see long‑term growth potential.

Medtronic insider sales: Marinaro sells 10,420 shares, CEO sells 50,000, reflecting routine portfolio shifts amid post‑MiniMed split focus.

George Simeon’s latest insider trade shows confidence in CRISPR Therapeutics’ gene‑editing future—buying shares at €14 while monetizing options near €50, hinting at potential upside.

Insider selling by Michael Schmertzler at PTC Therapeutics signals potential confidence issues amid a steep decline—watch Q3 earnings for a possible turnaround.

AKARI THERAPEUTICS insider buys reveal executive confidence amid a steep price drop, highlighting potential upside in its anti‑inflammatory pipeline and long‑term strategy.

Explore how MAPLIGHT THERAPEUTICS’ insider sell‑to‑cover moves reflect routine vesting rather than panic, and what the mixed buying signals mean for investors.

Danaher’s latest insider filings reveal no new trades, underscoring steady executive confidence and a strong growth trajectory for investors.

Melissa B. Cummings’ recent PROGYNY insider sell‑trades show routine portfolio management, not distress—her continued stake signals confidence in the company’s growth and menopause‑focused benefits.

United Therapeutics’ CEO’s 10b5‑1 trades show disciplined equity management, while its oral prostacyclin pipeline and digital‑health focus promise higher value‑based reimbursement and better patient outcomes.